---
run_id: halo-evidence-vs-diagnosis-validation-v11-generic-advice-prompted-07
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
model_condition: generic_advice_prompted
run_number: 7
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 1024
seed: 705
prompt_source: condition packet (generic_advice_prompted) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 18fa1d51f6167dbbf1f7ece676734d5cdb459384bca25e1508dd96cd4745e42d
source_packet: a short generic advice-quality request, then the frozen Advisor prompt; no rubric and no sources - see run-packet.md
source_packet_sha256: 31fa87bc7ee0d210ab5e0070b5421b72beac068fc006b3bc3be78b3dd242d5e7
condition_packet_sha256: 31fa87bc7ee0d210ab5e0070b5421b72beac068fc006b3bc3be78b3dd242d5e7
output_file: model-outputs/generic_advice_prompted-07.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - generic_advice_prompted (run 07)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v11-v1`, condition `generic_advice_prompted`, run 7 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 705, on the frozen condition packet.

## Output

I recommend that you commit to the **Claim File Review**.

### Reasoning: The "Illusion of Growth" Problem
Your current data is suffering from severe **signal contamination**. You have a "strong quarter," but the evidence suggests this is driven by sales incentives (bundle pricing) and managerial vanity (ops managers running samples for meetings), rather than genuine product-market fit with the end user (the adjuster).

The most alarming data point is the behavior of front-line adjusters: they use the tool for two days and then revert to manual notes. This indicates that SignalPath is likely perceived as a "management surveillance tool" or a "suggestion engine" that adds friction rather than reducing it. In B2B workflow software, if the end-user abandons the tool, the renewal is a ticking time bomb—regardless of what the buyer says during a bundle-discounted renewal window.

Here is why the other options are insufficient:
*   **Scale SignalPath Broadly:** This is high-risk. You are scaling a product that regional carriers are already planning to remove and adjusters are abandoning.
*   **Usage Quality Sprint:** This measures *quantity* of activity, not *quality* of outcome. You already know usage is up; you just don't know if that usage is productive or performative.
*   **Commercial Cleanroom:** This tests the *pricing/packaging* strategy, not the *product value*. It tells you if people will pay for it without a discount, but it doesn't tell you how to fix the product so they *want* to pay for it.
*   **Narrow to Health-Liability:** This is a premature pivot based on one segment's struggle with explainability. You don't yet know if the core value proposition is broken for everyone or just inhibited by regulation in one sector.

The **Claim File Review** is the only option that provides "ground truth." By auditing actual files, you move from *proxy metrics* (clicks and tickets) to *outcome metrics* (accepted vs. overridden suggestions). This will tell you if the product is actually solving the problem or if your "strong quarter" is simply a result of aggressive sales engineering.

### The Trade-off
By choosing the Claim File Review, you are displacing the **Usage Quality Sprint**. You give up the ability to track real-time behavioral trends across the entire install base in exchange for a deep, forensic understanding of why the product is failing or succeeding at the desk level. You are sacrificing *breadth* for *depth*.

### The Strongest Reason Against This Recommendation
The Claim File Review is slow, manual, and qualitative. In twelve days, the board wants a budget for "scaling" or "pivoting." A file review provides a diagnosis, not a growth engine. The CEO may find this approach too passive or "academic" when the sales team is currently reporting a winning streak. There is a risk that by focusing on the "broken" parts of the workflow, you dampen the commercial momentum created by the sales team.

### Evidence That Would Change My Mind
I would switch my recommendation to the **Commercial Cleanroom** if you could prove that the "abandonment" by adjusters is a training issue rather than a utility issue.

Specifically, if you found evidence that adjusters who received high-touch enablement continued to use SignalPath at a rate of >60% after the first month, then the product is sound and the problem is purely GTM/Enablement. In that case, testing the commercial viability (the Cleanroom) becomes the priority to ensure you aren't just "buying" growth with discounts.
